Every AXLRx Obesity report, across 5 report types. Each is scoped to your asset and verified to a live source.
Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality.
US adult obesity at 41.9% (CDC NHANES). BMI-class distribution, severe-obesity burden, and the comorbidity segments that drive coverage.
Why Medicare covers Wegovy only for cardiovascular risk, how the IRA's IPAY 2027 semaglutide price applies across the franchise, and ICER's 2025 'high value' verdict.
Wegovy lists at roughly $1,349 a month, but CMS pays $274 for a 30-day semaglutide supply starting 2027, a 71% cut that applies to Ozempic, Rybelsus, and Wegovy alike. Tirzepatide sits outside the negotiation entirely, for now.
Wegovy and Zepbound already occupy the injectable position. A new entrant must clear the 20.9% efficacy bar and price beneath the $274 IRA reset arriving in 2027.
AXLRx publishes Competitive Intelligence, Disease Landscape, Payer & HTA, Pricing Strategy Model, and Launch Readiness for Obesity. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Obesity coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Obesity reports were updated July 2026.